Gene
CDKN1A
CDKN1A is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (72), Actionable biomarkers (2), Trial mentions (6), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CDKN1A. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 2 at the structurally incomplete recent edge.
CDKN1A has 6 trial mentions across 6 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 1 of 8,738 | 0.01% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 21 of 11,460 | 0.18% |
| 2022 | 0 of 8,285 | 0.00% | 31 of 13,598 | 0.23% |
| 2021 | 0 of 8,692 | 0.00% | 39 of 15,045 | 0.26% |
| 2020 | 0 of 7,640 | 0.00% | 32 of 14,459 | 0.22% |
| 2019 | 0 of 7,300 | 0.00% | 34 of 12,159 | 0.28% |
| 2018 | 1 of 6,927 | 0.01% | 18 of 11,854 | 0.15% |
| 2017 | 0 of 6,558 | 0.00% | 32 of 11,595 | 0.28% |
Showing 10 of 37 years.
Assay-provider ledger (72)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Convergent Genomics | Diagnostic provider | Clinical validationAnalytical validation | 1 | September 15, 2023 |
| Agilent | Reagent supplier | Clinical validationAnalytical validation | 1 | May 05, 2021 |
| BIO-RAD | Reagent supplier | Clinical validationAnalytical validation | 1 | May 05, 2021 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 4 | May 05, 2021 +2 undated |
| TAKARA BIO | Reagent supplier | Clinical validationAnalytical validation | 1 | May 05, 2021 |
Showing 5 of 72 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CDKN1A oncogenic mutation | Cdk2/4 Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
| CDKN1A deletion | Cdk2/4 Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (6)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02576665 | Trial eligibility (AACT) |
| NCT07456371 | Trial eligibility (AACT) |
| NCT03452774 | Trial eligibility (AACT) |
| NCT01546038 | Trial outcomes (AACT) |
| NCT01472445 | Trial outcomes (AACT) |
Showing 5 of 6 trial mentions.
Target-disease associations (805)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 46,XX ovotesticular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX testicular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XY complete gonadal dysgenesis | cardiovascular disease | Mouse knockout (IMPC) |
| 46,XY disorder of sex development due to 5-alpha-reductase 2 deficiency | endocrine system disease | Mouse knockout (IMPC) |
| 46,XY disorder of sex development due to isolated 17,20 lyase deficiency | cancer or benign tumor | Mouse knockout (IMPC) |
Showing 5 of 805 associations.
Vendor sourcing (14)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.74T>G (p.V25G) alteration is located in exon 3 (coding exon 1) of the CDKN1A gene. This alteration results from a T to G substitution at nucleotide pos... | View ClinVar record SCV003625340.2 |
| Chongqing Precision Biotech Co., Ltd. (China) | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Received prior Chimeric Antigen Receptor T-cell (CAR-T) therapy or any other gene-modified cell therapy before screening. * Received any of the followin... | View trial NCT07456371 |
| Chongqing Precision Biotech Co., Ltd. (China) | Trial sponsor | Mentioned in trial textTrial free-text mention | PIC1 | View trial NCT07456371 |
| Forte Biosciences, Inc. | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Patient has given written informed consent. 2. Patient is between 18 and 75 years of age, inclusive. 3. Patient has an advanced malignancy that has pro... | View trial NCT02576665 |
| Forte Biosciences, Inc. | Trial sponsor | Mentioned in trial textTrial free-text mention | CDKN1A | View trial NCT02576665 |
Showing 5 of 14 sourcing records.
Trial-cited literature (504)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Sodium valproate, a potential repurposed treatment for the neurodegeneration in Wolfram syndrome (TREATWOLFRAM): trial protocol for a pivotal multicentre, randomised double-blind controlled trial. | BMJ open | 2025 | 6 |
| Normal bronchial field basal cells show persistent methylome-wide impact of tobacco smoking, including in known cancer genes. | Epigenetics | 2025 | 2 |
| Drugging p53 in cancer: one protein, many targets. | Nature reviews. Drug discovery | 2023 | 569 |
| OxPhos defects cause hypermetabolism and reduce lifespan in cells and in patients with mitochondrial diseases. | Communications biology | 2023 | 127 |
| Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. | Nature | 2023 | 115 |
Showing 5 of 504 papers.
Protein variant mentions (1)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.S31R | 1 | 2007 | PMID 17293864 |
Literature-extracted relations (101)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Valproic Acid | Chemical | positive_correlate |
Sodium valproate, a potential repurposed treatment for the neurodegeneration in Wolfram syndrome (TREATWOLFRAM): trial protocol for a pivotal multicentre, randomised double-blind controlled trial. | 2025 |
| Epirubicin | Chemical | associate |
EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. | 2021 |
| Ozone | Chemical | associate |
Effects of mild ozonisation on gene expression and nuclear domains organization in vitro. | 2017 |
| Lipopolysaccharides | Chemical | positive_correlate |
Neutrophil-Expressed p21/waf1 Favors Inflammation Resolution in Pseudomonas aeruginosa Infection. | 2016 |
| Irinotecan | Chemical | positive_correlate |
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. | 2015 |
Showing 5 of 101 relation assertions.
Organizations publishing (419)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Harvard Medical School | Academic | 17 | 2000 to 2022 |
| Government of the United States of America | Government | 16 | 1997 to 2023 |
| Dana-Farber Cancer Institute | Other | 14 | 2000 to 2022 |
| The University of Texas System | Academic | 13 | 2003 to 2021 |
| Mass General Brigham | Hospital | 10 | 2010 to 2023 |
Showing 5 of 419 organizations.
Where CDKN1A appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
714 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.